Risankizumab for Ulcerative Colitis
Listen now
Description
Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis.
Related Content:
Monoclonal Antibody Risankizumab for Ulcerative Colitis Risankizumab for Ulcerative Colitis
More Episodes
Transfusion strategy for patients with acute brain injury, telehealth care, acute kidney injury after cardiac surgery, and weaning ventilatory support are the topics of 4 trials published in JAMA and presented at the 2024 European Society of Intensive Care Medicine meeting. JAMA Associate Editor...
Published 10/09/24
Gastric cancer is a leading cause of cancer death globally. Chronic H pylori infection is the primary cause of gastric cancer, responsible for at least 80% of the new cases. Constanza Camargo, PhD, of the National Cancer Institute joins JAMA Associate Editor John M. Inadomi, MD, to discuss...
Published 09/30/24
Fever is associated with worse outcomes in patients with stroke, but whether preventing fever improves outcomes is unclear. David M. Greer, MD, MA, speaks with JAMA Associate Editor Jeffrey L. Saver, MD, about fever prevention in patients with acute stroke and its impact on functional outcomes.
...
Published 09/25/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
